QC
PRQR icon

Quadrature Capital’s ProQR Therapeutics PRQR Stock Holding History

Quadrature Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Sell
12,035
-92,196
-88% -$151K ﹤0.01% 1312
2025
Q4 		$211K Buy
104,231
+68,091
+188% +$159K ﹤0.01% 958
2025
Q3 		$77.2K Buy
+36,140
New +$79K ﹤0.01% 912
2025
Q2 		– Sell
-26,403
Closed -$35.4K – 1393
2025
Q1 		$35.4K Buy
+26,403
New +$56.2K ﹤0.01% 1002

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Quadrature Capital's PRQR Position: Q1 2026 in Review

Quadrature Capital reduced its ProQR Therapeutics (PRQR) stake by 88% in Q1 2026, selling an estimated $151K and leaving 12,035 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

Quadrature Capital first reported a position in PRQR in Q1 2025 and has held it in 4 quarters since. The position peaked at $211K in Q4 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Quadrature Capital held 12,035 shares of ProQR Therapeutics worth $19.5K as of Q1 2026.
  • Quadrature Capital sold 92,196 ProQR Therapeutics shares in Q1 2026, an estimated $151K.
  • ProQR Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1312 holding.
  • Quadrature Capital first reported a position in ProQR Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Quadrature Capital's ProQR Therapeutics position peaked at $211K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.